225 related articles for article (PubMed ID: 21833557)
1. Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer.
Sadar MD
World J Urol; 2012 Jun; 30(3):311-8. PubMed ID: 21833557
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity.
Sadar MD
Cancer Res; 2011 Feb; 71(4):1208-13. PubMed ID: 21285252
[TBL] [Abstract][Full Text] [Related]
3. In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer.
Shen HC; Shanmugasundaram K; Simon NI; Cai C; Wang H; Chen S; Balk SP; Rigby AC
Mol Endocrinol; 2012 Nov; 26(11):1836-46. PubMed ID: 23023563
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor antagonists in castration-resistant prostate cancer.
Rathkopf D; Scher HI
Cancer J; 2013; 19(1):43-9. PubMed ID: 23337756
[TBL] [Abstract][Full Text] [Related]
5. An androgen receptor N-terminal domain antagonist for treating prostate cancer.
Myung JK; Banuelos CA; Fernandez JG; Mawji NR; Wang J; Tien AH; Yang YC; Tavakoli I; Haile S; Watt K; McEwan IJ; Plymate S; Andersen RJ; Sadar MD
J Clin Invest; 2013 Jul; 123(7):2948-60. PubMed ID: 23722902
[TBL] [Abstract][Full Text] [Related]
6. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer.
Mohler ML; Sikdar A; Ponnusamy S; Hwang DJ; He Y; Miller DD; Narayanan R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672769
[TBL] [Abstract][Full Text] [Related]
7. New hormonal therapies for castration-resistant prostate cancer.
Mostaghel EA; Plymate S
Endocrinol Metab Clin North Am; 2011 Sep; 40(3):625-42, x. PubMed ID: 21889725
[TBL] [Abstract][Full Text] [Related]
8. Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC.
Ji Y; Zhang R; Han X; Zhou J
Eur J Med Chem; 2023 Feb; 247():115077. PubMed ID: 36587421
[TBL] [Abstract][Full Text] [Related]
9. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
[TBL] [Abstract][Full Text] [Related]
10. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
11. Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target.
Ferroni C; Varchi G
Curr Med Chem; 2019; 26(33):6053-6073. PubMed ID: 30209993
[TBL] [Abstract][Full Text] [Related]
12. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor antagonists for prostate cancer therapy.
Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
[TBL] [Abstract][Full Text] [Related]
14. Lessons from in-vivo models of castration-resistant prostate cancer.
Lin D; Gout PW; Wang Y
Curr Opin Urol; 2013 May; 23(3):214-9. PubMed ID: 23385975
[TBL] [Abstract][Full Text] [Related]
15. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
Schalken J; Fitzpatrick JM
BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
[TBL] [Abstract][Full Text] [Related]
16. Antiandrogens in prostate cancer.
Reid P; Kantoff P; Oh W
Invest New Drugs; 1999; 17(3):271-84. PubMed ID: 10665479
[TBL] [Abstract][Full Text] [Related]
17. Targeting the androgen receptor pathway in prostate cancer.
Chen Y; Sawyers CL; Scher HI
Curr Opin Pharmacol; 2008 Aug; 8(4):440-8. PubMed ID: 18674639
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor variants: RNA-based mechanisms and therapeutic targets.
Tietz KT; Dehm SM
Hum Mol Genet; 2020 Sep; 29(R1):R19-R26. PubMed ID: 32412639
[TBL] [Abstract][Full Text] [Related]
19. Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer.
Zhang Y; Castaneda S; Dumble M; Wang M; Mileski M; Qu Z; Kim S; Shi V; Kraft P; Gao Y; Pak J; Sapra P; Bandaru R; Zhao H; Vessella RL; Horak ID; Greenberger LM
Mol Cancer Ther; 2011 Dec; 10(12):2309-19. PubMed ID: 22027692
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
Taplin ME
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
